141 related articles for article (PubMed ID: 32485981)
1. Fibroblasts as a Biological Marker for Curative Resection in Pancreatic Ductal Adenocarcinoma.
Katsuta E; Rashid OM; Takabe K
Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32485981
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma.
Park H; Lee Y; Lee H; Kim JW; Hwang JH; Kim J; Yoon YS; Han HS; Kim H
Tumour Biol; 2017 Oct; 39(10):1010428317718403. PubMed ID: 29025374
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
[TBL] [Abstract][Full Text] [Related]
4. Pancreatic adenocarcinomas with mature blood vessels have better overall survival.
Katsuta E; Qi Q; Peng X; Hochwald SN; Yan L; Takabe K
Sci Rep; 2019 Feb; 9(1):1310. PubMed ID: 30718678
[TBL] [Abstract][Full Text] [Related]
5. Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen.
Ogawa Y; Masugi Y; Abe T; Yamazaki K; Ueno A; Fujii-Nishimura Y; Hori S; Yagi H; Abe Y; Kitago M; Sakamoto M
Clin Cancer Res; 2021 Jan; 27(1):107-119. PubMed ID: 33046515
[TBL] [Abstract][Full Text] [Related]
6. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study.
Nahm CB; Turchini J; Jamieson N; Moon E; Sioson L; Itchins M; Arena J; Colvin E; Howell VM; Pavlakis N; Clarke S; Samra JS; Gill AJ; Mittal A
Eur J Surg Oncol; 2019 Feb; 45(2):218-224. PubMed ID: 30348604
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression in pancreatic ductal adenocarcinoma is a poor prognostic factor in patients with high CD8
Yamaki S; Yanagimoto H; Tsuta K; Ryota H; Kon M
Int J Clin Oncol; 2017 Aug; 22(4):726-733. PubMed ID: 28314962
[TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of NRAS Overexpression in Resectable Pancreatic Adenocarcinoma Patients.
Martinez-Useros J; Li W; Georgiev-Hristov T; Fernandez-Aceñero MJ; Borrero-Palacios A; Perez N; Celdran A; Garcia-Foncillas J
Pathol Oncol Res; 2019 Jan; 25(1):269-278. PubMed ID: 29101736
[TBL] [Abstract][Full Text] [Related]
9. Disease spectrum of intraductal papillary mucinous neoplasm with an associated invasive carcinoma invasive IPMN versus pancreatic ductal adenocarcinoma-associated IPMN.
Kang MJ; Lee KB; Jang JY; Kwon W; Park JW; Chang YR; Kim SW
Pancreas; 2013 Nov; 42(8):1267-74. PubMed ID: 24308063
[TBL] [Abstract][Full Text] [Related]
10. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
11. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
12. Cancer-associated fibroblasts in pancreatic adenocarcinoma.
Pan B; Liao Q; Niu Z; Zhou L; Zhao Y
Future Oncol; 2015 Sep; 11(18):2603-10. PubMed ID: 26284509
[TBL] [Abstract][Full Text] [Related]
13. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative Plasma miR-21-5p Is a Sensitive Biomarker and Independent Prognostic Factor in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Surgical Resection.
Karasek P; Gablo N; Hlavsa J; Kiss I; Vychytilova-Faltejskova P; Hermanova M; Kala Z; Slaby O; Prochazka V
Cancer Genomics Proteomics; 2018; 15(4):321-327. PubMed ID: 29976637
[TBL] [Abstract][Full Text] [Related]
15. Histopathological tumor invasion of the mesenterico-portal vein is characterized by aggressive biology and stromal fibroblast activation.
Lapshyn H; Bolm L; Kohler I; Werner M; Billmann FG; Bausch D; Hopt UT; Makowiec F; Wittel UA; Keck T; Bronsert P; Wellner UF
HPB (Oxford); 2017 Jan; 19(1):67-74. PubMed ID: 27825542
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer.
Bronsert P; Kohler I; Timme S; Kiefer S; Werner M; Schilling O; Vashist Y; Makowiec F; Brabletz T; Hopt UT; Bausch D; Kulemann B; Keck T; Wellner UF
Surgery; 2014 Jul; 156(1):97-108. PubMed ID: 24929761
[TBL] [Abstract][Full Text] [Related]
17. L1 Cell adhesion molecule (L1CAM) expression at the cancer invasive front is a novel prognostic marker of pancreatic ductal adenocarcinoma.
Tsutsumi S; Morohashi S; Kudo Y; Akasaka H; Ogasawara H; Ono M; Takasugi K; Ishido K; Hakamada K; Kijima H
J Surg Oncol; 2011 Jun; 103(7):669-73. PubMed ID: 21360711
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of CD20 Positive B-Cells and B-Cell Aggregates in the Tumor Infiltration Zone is Associated with Better Survival of Patients with Pancreatic Ductal Adenocarcinoma.
Brunner M; Maier K; Rümmele P; Jacobsen A; Merkel S; Benard A; Krautz C; Kersting S; Grützmann R; Weber GF
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32150869
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast activation protein-α-expressing fibroblasts promote the progression of pancreatic ductal adenocarcinoma.
Kawase T; Yasui Y; Nishina S; Hara Y; Yanatori I; Tomiyama Y; Nakashima Y; Yoshida K; Kishi F; Nakamura M; Hino K
BMC Gastroenterol; 2015 Sep; 15():109. PubMed ID: 26330349
[TBL] [Abstract][Full Text] [Related]
20. Stromal Palladin Expression Is an Independent Prognostic Factor in Pancreatic Ductal Adenocarcinoma.
Sato D; Tsuchikawa T; Mitsuhashi T; Hatanaka Y; Marukawa K; Morooka A; Nakamura T; Shichinohe T; Matsuno Y; Hirano S
PLoS One; 2016; 11(3):e0152523. PubMed ID: 27023252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
